Drugs / AIR645
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00658749 | Apr 2008 → Apr 2009 | asthma | Altair Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00941577 | Oct 2009 → May 2010 | asthma | Altair Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIR645 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00658749 ↗ |
| Action | Inhibit | “AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor)” NCT00658749 ↗ |
| Route | Other | “AIR645 (blinded) by nebulization” NCT00658749 ↗ |